Key result
InFlow transcatheter valve shows good hemodynamics and biocompatibility at 180 days in an ovine model.
Why the study?
To evaluate the bio-functionality of a novel, proprietary balloon-expandable biological TAVI system in an ovine model of aortic banding.
The novel InFlow balloon-expandable biological transcatheter heart valve showed favorable hemodynamics and biocompatibility in a preclinical ovine model, supporting its potential as a viable TAVI alternative.
Answers are grounded in this paper and cite their sources.
Supports first-in-human evaluation of the InFlow valve; leaves open clinical performance and durability.
BACKGROUND: The aim of the study was to evaluate bio-functionality of a novel, proprietary balloon-expandable biological transcatheter aortic valve implantation (TAVI) system (InFlow, CardValve Consortium, Poland) in an ovine model of aortic banding. METHODS: Surgical ascending aorta banding was created in 21 sheep. Two weeks later, 18 biological valves were implanted within the model using 15-16 F InFlow TAVI systems and carotid cut-down approach. Follow-up transthoracic echocardiography was performed at 30, 90, and 180-day. At designated time, animals were euthanized and valves harvested for analysis. RESULTS: All sheep survived the banding procedure. There were 4 (22%) procedure related deaths within a 7-day period. During the observation an additional 2 sheep died. In one, the valve dislocated after the procedure - the animal was excluded. Two animals completed 30-day follow up, five 90-day follow-up and four terminal follow-up of 180 days. Valves examined via transesophageal echocardiography showed proper hemodynamic parameters without evidence of structural valve deterioration. The maximum and average flow gradients at 180 days were 31.4 (23.3-37.7) and 17.5 (13.1-20.2) mmHg, respectively. There was one case of moderate insufficiency and no case of perivalvular leaks. By histopathology, there were no inflammation, thrombosis, nor calcifications in any tested valves at long-term follow-up. Neointimal coverage of stent struts increased with time from basal part in "early" groups to nearly 3/4 of stent length in the 180-day group. The pannus tissue showed maturation that increased with time with no stenotic "collar" visible in orthotopically implanted valves. CONCLUSIONS: The study showed good hemodynamic performance, durability and biocompatibility of the novel biological THV.
No takes yet. Share an insight, caveat, or question.
Buszman et al. (2023) studied Aortic stenosis (ovine aortic banding model) (n=21). InFlow biological transcatheter heart valve was evaluated on Bio-functionality and hemodynamic performance. The InFlow biological transcatheter heart valve showed good hemodynamic performance and biocompatibility in an ovine model, with maximum and average flow gradients of 31.4 and 17.5 mmHg at 180 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: